- Home
- BUD vs VRTX Comparison
BUD vs VRTX Comparison
Compare BUD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUD
- VRTX
- Stock Information
- Founded
- BUD 1366
- VRTX 1989
- Country
- BUD Belgium
- VRTX United States
- Employees
- BUD N/A
- VRTX N/A
- Industry
- BUD Beverages (Production/Distribution)
- VRTX EDP Services
- Sector
- BUD Consumer Staples
- VRTX Technology
- Exchange
- BUD Nasdaq
- VRTX Nasdaq
- Market Cap
- BUD 136.0B
- VRTX 115.6B
- IPO Year
- BUD N/A
- VRTX 1991
- Fundamental
- Price
- BUD $61.78
- VRTX $369.10
- Analyst Decision
- BUD Strong Buy
- VRTX Buy
- Analyst Count
- BUD 4
- VRTX 24
- Target Price
- BUD $72.00
- VRTX $496.76
- AVG Volume (30 Days)
- BUD 2.7M
- VRTX 1.9M
- Earning Date
- BUD 07-31-2025
- VRTX 08-04-2025
- Dividend Yield
- BUD 1.38%
- VRTX N/A
- EPS Growth
- BUD 21.01
- VRTX N/A
- EPS
- BUD 3.50
- VRTX 14.07
- Revenue
- BUD $58,520,000,000.00
- VRTX $11,418,800,000.00
- Revenue This Year
- BUD $2.37
- VRTX $10.40
- Revenue Next Year
- BUD $5.40
- VRTX $10.63
- P/E Ratio
- BUD $17.54
- VRTX $26.70
- Revenue Growth
- BUD N/A
- VRTX 10.46
- 52 Week Low
- BUD $45.94
- VRTX $372.35
- 52 Week High
- BUD $72.13
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- BUD 38.38
- VRTX 27.85
- Support Level
- BUD $56.97
- VRTX $372.35
- Resistance Level
- BUD $67.11
- VRTX $473.37
- Average True Range (ATR)
- BUD 0.95
- VRTX 12.86
- MACD
- BUD -0.50
- VRTX -11.52
- Stochastic Oscillator
- BUD 33.04
- VRTX 2.92
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.